Abstract:e13574 Background: Emerging evidence has proven that tertiary lymphoid structures (TLSs) are predictive biomarkers of favorable clinical outcomes in melanoma, whereas the exact role of TLS-related genes remained unclear. In the present study, we aimed to establish a novel risk-scoring model based on TLS-related genes to predict the prognosis and immunotherapeutic efficacy in cutaneous melanoma. Methods: Patients in the TCGA-SKCM cohort (n = 468) were clustered into two subtypes based on the prognosis-related genes associated with TLSs though consensus clustering analysis, and differentially expressed genes were screened between two clusters. By univariate and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis, a 13-gene signature was selected to construct a prognostic risk-scoring model. The median risk score served as the unified cutoff to divide patients into high- and low-risk groups. GSE65904 (n = 220) and GSE544467 (n = 79) cohorts were used for external validation. Univariate and multivariate cox analysis were used to select significant variables for construction of nomogram. The nomogram model was evaluated by concordance index, time-dependent receiver operating characteristics (ROC) curve, calibration curve and decision curve analysis (DCA). GSEA, CIBERSORT, Tumor Immune Dysfunction and Exclusion (TIDE) and Immunophenoscore (IPS) were utilized to explore the potential mechanism of immune-related process and immunotherapy. Results: Thirteen signature genes (CCL8, DLX3, CNTFR, CNFN, BCAN, CD33, HAPLN3, ABCB1, CLIC2, GCNT1, FGF1, A2ML1, GBP2) were developed to construct a risk-scoring model. Melanoma patients could be grouped into high- and low-risk groups, and low-risk patients showed better survival than high-risk patients. Area under the curve values of 1, 3, and 5 years were 0.76, 0.72, and 0.73 in the training set, respectively, indicating a good predictive efficacy. In addition, based on independent prognostic factors including risk score, age, stage, T and N Staging after univariate and multivariate Cox regression analyses, a nomogram was constructed to better estimate individual survival. For the prediction of 1, 3, and 5-year overall survival probability according to the nomogram, the area under the receiver operating characteristic curve was 0.81, 0.80 and 0.76, respectively. Furthermore, we explored the correlation of the prognostic risk-scoring model with tumor microenvironment (TME) and immunotherapeutic efficacy. Patients in the low risk group featured immunoactive TME, higher IPS scores and lower TIDE scores, and was regarded as the potential beneficiaries of immunotherapy. Conclusions: The 13-gene risk score proposed in the research may provide new insights into the individualized evaluation of cutaneous melanoma prognosis and Immunotherapeutic Efficacy

Development and validation of Cellular Senescence-Related Gene Signature for predicting the survival and immunotherapeutic responses in Skin Cutaneous Melanoma

Development and Validation of an Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma

Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma

Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma

Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma

Development and Validation of an Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma

Identification and Validation of Three Risk Models in Skin Melanoma Based on Bioinformatics Analysis

Characterization of coagulation-related gene signature to predict prognosis and tumor immune microenvironment in skin cutaneous melanoma

Development and Validation of a Novel T Cell Proliferation-Related Prognostic Model for Predicting Survival and Immunotherapy Benefits in Melanoma

Development of a novel senescence‐related gene signature to predict clinical outcomes, immune landscape, and chemotherapeutic sensitivity in oral squamous cell carcinoma

Identification of the ageing-related prognostic gene signature, and the associated regulation axis in skin cutaneous melanoma

Identification of anoikis-related subtypes and development of risk stratification system in skin cutaneous melanoma

Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma

The Role of SRGN in the Survival and Immune Infiltrates of Skin Cutaneous Melanoma (SKCM) and SKCM-metastasis Patients

Identification of Lactate-Related Gene Signature for Prediction of Progression and Immunotherapeutic Response in Skin Cutaneous Melanoma

A novel risk-scoring model developed based on tertiary lymphoid structure related genes predict the prognosis and immunotherapeutic efficacy in cutaneous melanoma.

Bulk and single-cell RNA-sequencing analyses along with abundant machine learning methods identify a novel monocyte signature in SKCM

A Prognostic Signature Associated with Cell Senescence Predicts Survival Outcomes and Strongly Associates with Immunotherapy and Chemotherapy Response in Breast Cancer

Identification of senescence-related subtypes, establishment of a prognosis model, and characterization of a tumor microenvironment infiltration in breast cancer

Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM

Identification of a cellular senescence-related-lncRNA (SRlncRNA) signature to predict the overall survival of glioma patients and the tumor immune microenvironment